Biochem/physiol Actions
ATP-competitive dual BCR-ABL and Src kinase inhibitor
PD166326 is an ATP-competitive dual BCR-ABL and Src kinase inhibitor. In some studies it has been found to be more potent than imatinib with inhibition of cancer growth in the low nanomolar range or even picomolar range in various biological systems.
Legal Information
Pfizer is a registered trademark of Pfizer, Inc.
| Colour | white to light brown |
|---|---|
| Quality Level | 100 |
| Manufacturer | SIGMA-ALDRICH |
| Solubility | DMSO: 2 mg/mL, clear |
| Form | powder |
| Assay | ≥98% (HPLC) |
There are no downloads for this product.
